PacBio (NASDAQ: PACB) announced on October 15, 2025 that it has introduced SPRQ‑Nx sequencing chemistry for its Revio and Vega platforms, a development that will lower the cost of HiFi genome sequencing by up to 40% to less than $300 per genome for customers operating at scale.
The new chemistry also adds 5hmC detection for epigenetic profiling and incorporates 21 CFR Part 11 compliance features for Vega, enabling regulated laboratories to use the benchtop system for clinical and production‑scale applications. Beta testing of SPRQ‑Nx on Revio is slated to begin in November 2025, with full commercial availability planned for 2026.
CEO Christian Henry said the cost savings and multi‑omic capabilities will “make HiFi sequencing accessible for every genome and every lab,” positioning PacBio to capture larger population‑genomics and AI‑modeling projects that require high‑quality, multi‑modal data. The enhancements are expected to drive higher consumable pull‑through and broaden the addressable market for PacBio’s long‑read technology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.